Economic and humanistic impact of Duchenne muscular dystrophy on patients, caregivers, families, and society: a literature review

Background Duchenne muscular dystrophy (DMD) is a severe, progressive disease with broad economic and humanistic impact, yet prior reviews and value assessments have focused on narrow definitions of disease burden. This study comprehensively evaluated the economic and humanistic impact of DMD for all stakeholders (patients, caregivers/families, payers [U.S. insurer], and society) in the U.S. Methods A targeted literature review following PRISMA guidelines was conducted in Embase and PubMed. Studies from January 1, 2018 to November 21, 2024, were included if direct medical or non-medical costs, indirect costs, or quality of life (QoL) outcomes were reported for individuals with DMD, caregivers/families, payers, or society. Results Fifty-three publications were included. Seven publications reported direct payer costs, which increased as DMD progressed. Patient/caregiver/family costs were captured in 11 studies reporting direct medical and/or non-medical costs (medical care, formal caregiving, home/vehicle modifications), 10 studies reporting indirect costs (e.g., productivity loss for caregivers, work-years and income lost by patients), and 35 publications reporting QoL outcomes (health-state utilities, psychological/emotional/social/physical health, and sibling/family spillover). Societal costs were reported in 3 web-based survey publications evaluating the types of financial support received, including for home/vehicle expenses, caregiving compensation, school aide support, and social program utilization. Conclusion Using a broader definition of DMD impact revealed the extensive economic and humanistic burden experienced across multiple stakeholders in the U.S. Traditional value assessments that focus solely on payer costs and health-state utilities fail to comprehensively capture the full burden, particularly for a severe, progressive disease like DMD with impacts beyond the patient.

Authors

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-19
DOI
https://doi.org/10.1186/s13023-026-04705-8
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Economic and humanistic impact of Duchenne muscular dystrophy on patients, caregivers, families, and society: a literature review

Alexa C. Klimchak, Katherine L. Gooch, C Abreu, Quinn Levin et al.
Orphanet Journal of Rare Diseases
Health Systems, Economic Evaluations, Quality of Life
article

Economic and humanistic impact of Duchenne muscular dystrophy on patients, caregivers, families, and society: a literature review

Alexa C. Klimchak, Katherine L. Gooch, C Abreu, Quinn Levin, Madeline Dec, Theresa Schmidt, Kendall Logan
article en

Abstract

Background Duchenne muscular dystrophy (DMD) is a severe, progressive disease with broad economic and humanistic impact, yet prior reviews and value assessments have focused on narrow definitions of disease burden. This study comprehensively evaluated the economic and humanistic impact of DMD for all stakeholders (patients, caregivers/families, payers [U.S. insurer], and society) in the U.S. Methods A targeted literature review following PRISMA guidelines was conducted in Embase and PubMed. Studies from January 1, 2018 to November 21, 2024, were included if direct medical or non-medical costs, indirect costs, or quality of life (QoL) outcomes were reported for individuals with DMD, caregivers/families, payers, or society. Results Fifty-three publications were included. Seven publications reported direct payer costs, which increased as DMD progressed. Patient/caregiver/family costs were captured in 11 studies reporting direct medical and/or non-medical costs (medical care, formal caregiving, home/vehicle modifications), 10 studies reporting indirect costs (e.g., productivity loss for caregivers, work-years and income lost by patients), and 35 publications reporting QoL outcomes (health-state utilities, psychological/emotional/social/physical health, and sibling/family spillover). Societal costs were reported in 3 web-based survey publications evaluating the types of financial support received, including for home/vehicle expenses, caregiving compensation, school aide support, and social program utilization. Conclusion Using a broader definition of DMD impact revealed the extensive economic and humanistic burden experienced across multiple stakeholders in the U.S. Traditional value assessments that focus solely on payer costs and health-state utilities fail to comprehensively capture the full burden, particularly for a severe, progressive disease like DMD with impacts beyond the patient.

Orphanet Journal of Rare Diseases
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon